Literature DB >> 25489692

American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer.

Adam G Mace1, Rish K Pai, Luca Stocchi, Matthew F Kalady.   

Abstract

BACKGROUND: The American Joint Committee on Cancer and the College of American Pathologists provide guidelines for reporting pathologic response to neoadjuvant treatment of rectal cancer. The clinical relevance of these tumor regression grading guidelines is undefined.
OBJECTIVE: This study evaluates the prognostic significance of the American Joint Committee on Cancer/College of American Pathologists regression grading.
DESIGN: This is a retrospective cohort study based on data from a prospectively maintained colorectal cancer database. The cohorts were defined by American Joint Committee on Cancer/College of American Pathologists tumor regression grade.
SETTING: This study was performed at a single tertiary referral center. PATIENTS: Five hundred thirty-eight patients with primary rectal adenocarcinoma who underwent neoadjuvant therapy between 1992 and 2012 were identified. MAIN OUTCOME MEASURES: The primary outcome measures were overall and disease-free survival, cancer-specific mortality, and cumulative recurrence rate.
RESULTS: Five hundred thirty-eight patients were included, 105 of whom (19.5%) were American Joint Committee on Cancer/College of American Pathologists grade 0, 153 patients (28.4%) were grade 1, 181 patients (33.6%) were grade 2, and 99 (18.4%) were grade 3. Kaplan-Meier analysis revealed that American Joint Committee on Cancer/College of American Pathologists grade was associated with significant differences in overall survival (p < 0.001), disease-free survival (p < 0.001), and cumulative recurrence (p < 0.001). No local recurrences were observed in American Joint Committee on Cancer/College of American Pathologists grade 0 patients. Five-year overall survival rates were 89%, 74%, 63%, and 40% (p < 0.001); 5-year disease-free survival rates were 85%, 64%, 54%, and 33% (p < 0.001); and 5-year recurrence rates were 7%, 18%, 25%, and 33% (p <0.001) for American Joint Committee on Cancer/College of American Pathologists grades 0, 1, 2, and 3. After adjusting for significant covariates, including pathologic stage, American Joint Committee on Cancer/College of American Pathologists grade remained an independent predictor of overall survival (p < 0.001), disease-free survival (p < 0.001), and cumulative recurrence (p < 0.001) in Cox regression analyses. LIMITATIONS: This was a retrospective study. There was a low local recurrence rate in our population, limiting the sensitivity of recurrence analyses.
CONCLUSIONS: This is the first study to delineate American Joint Committee on Cancer/College of American Pathologists regression grade as an independent oncologic prognostic factor. This information can be used in discussions with patients who have rectal cancer.

Entities:  

Mesh:

Year:  2015        PMID: 25489692     DOI: 10.1097/DCR.0000000000000266

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  43 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Authors:  Hai-Yang Chen; Li-Li Feng; Ming Li; Huai-Qiang Ju; Yi Ding; Mei Lan; Shu-Mei Song; Wei-Dong Han; Li Yu; Ming-Biao Wei; Xiao-Lin Pang; Fang He; Shuai Liu; Jian Zheng; Yan Ma; Chu-Yang Lin; Ping Lan; Mei-Jin Huang; Yi-Feng Zou; Zu-Li Yang; Ting Wang; Jin-Yi Lang; Guy R Orangio; Vitaliy Poylin; Jaffer A Ajani; Wei-Hu Wang; Xiang-Bo Wan
Journal:  Oncologist       Date:  2021-02-22

Review 3.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Prognostic influence of histopathological regression patterns in rectal adenocarcinoma receiving neoadjuvant therapy.

Authors:  Ma Jesús Fernández-Aceñero; Lourdes Estrada Muñoz; Javier Sastre Varela; Juan Antonio Corona Sánchez; Cristina Díaz Del Arco; Beatriz García Paredes; Sofía Córdoba Largo; Laura Del Puerto Nevado
Journal:  J Gastrointest Oncol       Date:  2017-02

5.  CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.

Authors:  Sylvain Ferrandon; Jennifer DeVecchio; Leonardo Duraes; Hanumant Chouhan; Georgios Karagkounis; Jacqueline Davenport; Matthew Orloff; David Liska; Matthew F Kalady
Journal:  Cancer Res       Date:  2019-11-08       Impact factor: 12.701

6.  Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer.

Authors:  Jung Wook Huh; Seong Hyeon Yun; Seok Hyung Kim; Yoon Ah Park; Yong Beom Cho; Hee Cheol Kim; Woo Yong Lee; Hee Chul Park; Doo Ho Choi; Joon Oh Park; Young Suk Park; Ho-Kyung Chun
Journal:  J Gastrointest Surg       Date:  2018-05-29       Impact factor: 3.452

7.  Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma.

Authors:  M J Fernández-Aceñero; M Granja; J Sastre; B García-Paredes; L Estrada
Journal:  Virchows Arch       Date:  2016-01-11       Impact factor: 4.064

Review 8.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

9.  Simvastatin enhances radiation sensitivity of colorectal cancer cells.

Authors:  Georgios Karagkounis; Jennifer DeVecchio; Sylvain Ferrandon; Matthew F Kalady
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

10.  One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).

Authors:  Germaine Wong; Richard L Hope; Kirsten Howard; Jeremy R Chapman; Antoni Castells; Simon D Roger; Michael J Bourke; Petra Macaskill; Robin Turner; Gabrielle Williams; Wai Hon Lim; Charmaine E Lok; Fritz Diekmann; Nicholas B Cross; Shaundeep Sen; Richard D M Allen; Steven J Chadban; Carol A Pollock; Allison Tong; Armando Teixeira-Pinto; Jean Y H Yang; Narelle Williams; Eric Hoi Kit Au; Anh Kieu; Laura James; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2019-04-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.